Pseudomonas aeruginosa (PA6206), IC Lung Infection Model, LD90-100
CONTACT CUSTOMER SERVICE
ADD TO FAVORITES
ADD TO PANEL
OVERVIEW
DOCUMENTS/REFERENCES
BIOLOGICAL INFORMATION
BACKGROUND INFORMATION
This model assesses the efficacy of test articles for protection against a lethal lung infection with cytotoxic clinical isolate of Pseudomonas aeruginosa in immune-competent mice. It may be used to assess efficacy of small molecules, vaccines and biologics.
SPECIES
Pseudomonas aeruginosa
STRAIN COMMON NAME
#6206
ORGANISM
Gram-negative Bacteria
INCUBATION CONDITIONS
Aerobic
ASSAY INFORMATION
ASSAY TYPE
In Vivo
TESTING INFORMATION
PROCEDURE SUMMARY
Groups of 10 BALB/c derived female mice weighing 18 ± 2 g are used. On day 0, animals are inoculated intranasally (0.02 mL/lung) of Pseudomonas aeruginosa aeruginosa (PA6206) after anesthesia with etomidate (~20 mg/kg, IV) or pentobarbital (40 mg/kg, IV). Vehicle and/or test substances are then administered (IV, PO, IP, or SC) 1 and 13 hours later (or per the client request). Mortality is recorded daily during the following 10 days. Prevention of mortality in 50 percent or more (≥ 50%) of the animals indicates significant activity.
CRITERIA FOR SIGNIFICANCE
> 50% of survival
TURNAROUND TIME
STANDARD
20 Days
CLINICAL RELEVANCE
THERAPEUTIC AREA
Infectious Disease
ADDITIONAL INFORMATION
BRAND
PDS
TESTING LOCATION
Taiwan - Taipei
OTHER INFORMATION
We will readily accommodate client-specified alterations. These studies are performed at our AAALAC accredited BSL-2 laboratory in Taipei, Taiwan. All aspects of this work are performed in general accordance with the Guide for the Care and Use of laboratory animals (National Academy Press, Washington, DC, 2011). The study protocol was approved by the Pharmacology Discovery Services IACUC and is performed with the oversight of veterinarians to assure the humane treatment of laboratory animals.
ITEM DOES NOT EXIST
© Copyright 2026, Pharmacology Discovery Services – Privacy Policy | Cookie Notice | Cookie Preferences